Last reviewed · How we verify
Prevention of Bacterial Endocarditis
Approved treatments
- Cleocin T · Pfizer
Cleocin T works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death. - Cleocin · Generic (originally Upjohn/Pfizer)
Lincosamide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with excellent anaerobic coverage. - E-Mycin · Generic (originally Abbott/Lilly)
- Benzamycin · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of Bacterial Endocarditis patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of Bacterial Endocarditis treatment landscape brief
- Prevention of Bacterial Endocarditis treatment updates RSS
Frequently asked questions about Prevention of Bacterial Endocarditis
What drugs treat Prevention of Bacterial Endocarditis?
Tracked treatments include Cleocin T, Cleocin, E-Mycin, Benzamycin.
What is the treatment for Prevention of Bacterial Endocarditis?
Standard treatment for Prevention of Bacterial Endocarditis includes Cleocin T, Cleocin, E-Mycin, Benzamycin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of Bacterial Endocarditis patent cliff · Prevention of Bacterial Endocarditis CI report
- Treatment: Cleocin T · Pfizer
- Treatment: Cleocin · Generic (originally Upjohn/Pfizer)
- Treatment: E-Mycin · Generic (originally Abbott/Lilly)
- Treatment: Benzamycin · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing